Literature DB >> 1673976

Effect of H1-receptor blockade on late cutaneous reactions to antigen: a double-blind, controlled study.

C W Bierman1, D Maxwell, E Rytina, M B Emanuel, T H Lee.   

Abstract

This study is of the effect of the blockade of histamine H1 receptors by a long-acting antihistamine on the immediate and late clinical response to antigen (Ag) and on the recruitment of eosinophils in the late-phase cutaneous reaction. Ten adult volunteers with late-phase reactions to the intradermal injection of either Dermatophagoides pteronyssinus or Phleum pratense (timothy) pollen performed a double-blind, crossover study. Each volunteer took astemizole, 10 mg, or identical placebo, daily for 2 weeks. Ag in the concentration that induced a late reaction in the screening visit was injected intradermally at the end of each drug period. The early reaction was measured serially for 30 minutes and the late reaction at 4 and 6 hours. Biopsies of the Ag and control sites were also performed at 6 hours. After a 6-week washout period, subjects then took the opposite medication for 2 weeks and returned for skin testing and biopsy. Skin testing demonstrated that astemizole inhibited the immediate response to both histamine and allergen but had no effect on the late response at 4 hours and at 6 hours. Biopsy specimens revealed no significant effect on eosinophil recruitment at 6 hours. We conclude that histamine H1-receptor blockade has no effect on the late cutaneous reaction to Ag.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673976     DOI: 10.1016/0091-6749(91)90425-n

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  2 in total

Review 1.  Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  J P Rihoux; S Mariz
Journal:  Clin Rev Allergy       Date:  1993

2.  Microvascular mechanisms of histamine-induced potentiation of leukocyte adhesion evoked by chemoattractants.

Authors:  H Thorlacius; J Raud; X Xie; P Hedqvist; L Lindbom
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.